Influence of the clinical profile of patients with refractory epilepsy on lamotrigine plasma concentration

• Autor(a) principal: Baldoni, André Oliveira
• Data de Publicação: 2018
• Outros Autores: Freitas-Lima, Priscila, Alexandre, Veriano, Ferreira, Flávia Isaura de Santi, Martinez, Edson Zangiacomi, Queiroz, Regina Helena Costa, Sakamoto, Americo Ceiki, Pereira, Leonardo Regis Leira
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/153778
• topic: Lamotrigine; Refractory Epilepsy; Drug interaction; Therapeutic drug monitoring

The purpose of this work was to evaluate the influence of the clinical profile on lamotrigine (LTG) plasma concentrations from patients with refractory epileptic seizures. In this cross-sectional study, therapeutic monitoring of LTG, and questionnaires with 75 patients with refractory epileptic seizures of a Hospital in Ribeirão Preto-SP-Brazil were performed. The multiple linear regression model was used to verify association between the LTG plasma concentrations and the independent variables. Covariance analysis was used to compare the mean LTG plasma concentration among the co-medication groups. The LTG plasma concentration was associated both with the LTG dosage (mg/kg/day) (p=0.0096) and with the use of first generation antiepileptic drugs (AED) (p<0.01), being carbamazepine (CBZ) and phenytoin (PHT), the AEDs showing the most prominent influence in reducing LTG plasma concentrations. Adverse events, adherence to the pharmacological treatment, and epileptic seizures frequency, did not show significant correlation with LTG plasma concentration values. The conclusion is that LTG plasma concentration is significantly influenced by the LTG dosage and by the concomitant use of a first generation AED.